Adviser Investments LLC Acquires 3,750 Shares of Johnson & Johnson (NYSE:JNJ)

Adviser Investments LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 5.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,899 shares of the company’s stock after purchasing an additional 3,750 shares during the quarter. Johnson & Johnson accounts for about 0.9% of Adviser Investments LLC’s portfolio, making the stock its 24th biggest position. Adviser Investments LLC’s holdings in Johnson & Johnson were worth $13,983,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of JNJ. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter valued at approximately $4,172,929,000. BlackRock Inc. boosted its holdings in shares of Johnson & Johnson by 2.6% in the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after buying an additional 4,982,885 shares in the last quarter. GQG Partners LLC grew its stake in shares of Johnson & Johnson by 1,109.4% during the 4th quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock worth $676,375,000 after purchasing an additional 3,627,424 shares during the period. State Street Corp boosted its stake in shares of Johnson & Johnson by 1.8% during the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after purchasing an additional 2,492,359 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. raised its stake in shares of Johnson & Johnson by 5,036.2% during the first quarter. Vaughan Nelson Investment Management L.P. now owns 1,227,558 shares of the company’s stock valued at $217,560,000 after purchasing an additional 1,203,658 shares during the period. 68.78% of the stock is currently owned by institutional investors.

Insider Activity

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $171.79 on Friday. The firm’s 50-day moving average price is $175.41 and its 200 day moving average price is $174.52. The firm has a market capitalization of $451.67 billion, a PE ratio of 25.01, a PEG ratio of 3.29 and a beta of 0.59. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a current ratio of 1.42, a quick ratio of 1.14 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the previous year, the firm posted $2.48 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.63%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on JNJ. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, July 8th. Credit Suisse Group upped their price target on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. The Goldman Sachs Group increased their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Citigroup dropped their price target on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Finally, SVB Leerink dropped their price target on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *